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Background: Angiosarcoma is an aggressive vascular neoplasm with a high propensity for local recurrence. Electrochemotherapy is an emerging
skin-directed therapy, exerting prominent cytotoxic activity, and antivascular effects. Its efficacy in angiosarcoma has not been investigated.
Methods: This multicenter retrospective analysis reviewed patients who underwent electrochemotherapy from 2007 to 2014 for superficial
advanced angiosarcomas. Bleomycin was administered intravenously and delivered within tumors by means of percutaneously applied electric
pulses, according to the European Standard Operating Procedures for Electrochemotherapy. Tumor assessment was performed using RECIST
(version 1.1). Toxicity (CTCAE, v4.0) and local progression-free survival (LPFS) were also evaluated.
Results: Nineteen patients (13 with locally advanced and 6 with metastatic angiosarcomas) were treated. Tumor sites were: scalp (n¼ 5), breast
(n¼ 8), other skin sites (n¼ 3), and soft tissue (n¼ 3). Target lesions (n¼ 54) ranged in size from 1.5 to 2.5 cm (median, 2 cm). Treatment was well
tolerated. After 2 months, an objective response was observed in 12/19 (63%) patients, complete in 8 (42%). One-year LPFS within treatment field
was 68%. Local symptom improvement included palliation of bleeding (5/19 patients) and pain relief (6/19 patients).
Conclusions: Electrochemotherapy may represent a new locoregional treatment for selected patients with superficial angiosarcomas.
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INTRODUCTION
Angiosarcomas represent a heterogeneous group of rare vascular
malignancies, accounting for less than 2% of all soft tissue
sarcomas [1]. They may occur at any anatomic site, most commonly
head and neck skin and breast, often in the field of previous radiotherapy
or chronic lymphedema [2]. Angiosarcomas usually present with high-
grade histology and multifocal disease, with a tendency for local
recurrence and distant metastases [3]. Generally, the patients with
cutaneous angiosarcoma fare significantly better than those with deep-
seated tumors [4,5]. Nevertheless, among all superficial sarcomas,
angiosarcoma shows a significantly lower local control (5-year local
recurrence-free survival, 24.9%) and survival (5-year overall survival,
25.4%) compared with other histotypes [6]. Despite multidisciplinary
approach and adherence to treatment guidelines are crucial for outcome
of sarcomas [7], optimal management of angiosarcoma has not been
defined yet, and relies on a combination of surgery, adjuvant radiation
and, in selected cases, chemotherapy [1,4,8]. Due to the high incidence
of disease multifocality and the complexity of primary site anatomy, the
local recurrence rate reported in scalp angiosarcomas ranges from 44%
to 100% and, in radiation-associated angiosarcomas, from 26% to
92% [8–15]. Also in the locally advanced and metastatic settings,
despite the activity of doxorubicin- and paclitaxel-based regimens,
patient outcome remains still unsatisfactory, progression free-survival
spanning between 4 and 8 months [16]. Furthermore, most patients are
older than 70 years [17] and the risk of treatment-related side effects
may discourage aggressive treatment. As a result, there is an unmet need
for treatment options in this field. Electrochemotherapy (ECT)
enhances the cytotoxic effect of two otherwise poorly permeant
agents, bleomycin and cisplatin, by means of short electric pulses,
which transiently permeabilise tumor cell membrane. As a result, an
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increased drug concentration can be achieved within tumors [18].
Moreover, ECT targets tumor blood flow by exploiting two different
antivascular mechanisms [19,20]. The first is a transient
vasoconstriction, which increases drug entrapment into tumor tissue;
the second is a delayed disrupting action on endothelial cells leading to
irrecoverable damage of tumor vessels and to a further decrease in
tumor circulation. Thanks to these antivascular effects, ECT is
particularly advantageous in patients with vascular neoplasms, such
as Kaposi sarcoma, as well as in bleeding tumors, irrespective of
histotype [20–22]. On these bases, it is conceivable that ECTmight also
be effective in other, more aggressive, vascular tumors. The aim of this
study was to evaluate the activity and safety of ECT in patients with
angiosarcoma.
PATIENTS AND METHODS
Patient Selection
This was a multi-institutional retrospective study, approved by the
local institutional review boards of participating centers. Patients with
locally advanced or metastatic angiosarcomas who underwent ECT
from July 2007 to May 2014 at eight Italian hospitals (Veneto Institute
of Oncology, Padova; Istituto Tumori Bari; La Sapienza University,
Rome; San Gallicano Dermatologic Institute, Rome; Citta della salute e
della scienza, Torino; Ospedale Oncologico A. Businco, Cagliari; San
Martino Hospital, Genova; II University of Naples) were identified.
Their cases were reviewed and follow-up information was obtained
from treating physicians. Patient data were acquired from medical,
operative and pathology reports and stored in a dedicated electronic
database. The diagnosis of angiosarcoma was confirmed by a dedicated
pathologist. ECT was offered upon multidisciplinary agreement, if
surgical resection was excluded and patients where not suitable for, or
refractory to, radiotherapy or systemic treatment. Standard ECT
selection criteria are detailed elsewhere [23]. In patients with
concomitant visceral disease, the indication to ECT was given to
patients with of symptomatic superficial tumors and when at least
3-month life expectancy was estimated. Each patient gave written
informed consent and was treated according to Good Clinical Practice
recommendations.
Treatment
ECT was performed according to the European Standard Operating
Procedures for ECT (ESOPE) [23]. The procedure was carried out
under general anaesthesia or mild general sedation, as appropriate.
Bleomycin was administered intravenously as a bolus, at the dose of
15,000 IU/m2. After an interval of 8min, short (8 pulses of 100ms
duration, at a repetition frequency of 5,000Hz), high-voltage
(400–960V) electric pulses were delivered to the tumor by means of
a needle electrode. Electrode conformation was chosen according to the
tumor characteristics. The electric pulses were generated by a square
wave pulse generator (CliniporatorTM, IGEA, Carpi, Italy) suitable for
clinical electroporation. Pulse application lasted between 8 and 28min
after the infusion of chemotherapy. The indication to further ECT cycles
included: (i) the achievement of partial response (PR) or stable disease
(SD) after the first ECT, (ii) the occurrence of disease progression or
recurrence within ECT field, or (iii) out-of-field progression.
Tumor Response and Toxicity
For each patient, we registered up to sevenmeasurable tumors (target
lesions). Before, and 1 and 2 months following ECT, their largest
diameter was measured by mean of a caliper and their sum was
calculated. Tumor response was evaluated by using modified Response
Evaluation Criteria in Solid Tumours (RECIST) [24]. No confirmatory
biopsies were performed in this study. Local and systemic toxicity were
graded according to the Common Terminology Criteria for Adverse
Events (CTCAE, v4.0). Pain level was assessed by a 10-point Verbal
Numerical Rating Scale (VNRS; 0¼ no pain; 1–2¼mild pain;
3–6¼moderate pain; 7–10¼ severe pain).
Statistical Analysis
The main analysis was descriptive. Time to response was calculated
from the date of the first ECT to the appearance of complete response
(CR) or PR, whichever came first. To do between-group comparisons
for binary parameters (i.e., tumor response, skin toxicity, and pain) we
used contingency tables and Fisher’s exact test. Local progression-free
survival (LPFS) indicated the time from ECT to local recurrence or
progression within ECT field. PFS was calculated from the date of ECT
to disease progression at any site, whichever came first. Overall survival
(OS) was calculated from the date of first ECT until patient disease-
specific death. Kaplan–Meier curves were generated to estimate LPFS
and OS. Two sided P values of 0.05 or less were deemed significant.
Statistical analysis was performed using the SPSS software (Statistical
Packages for Social Sciences, IBM, NY, U.S., version 17.0).
RESULTS
Patient Demographics and Tumor Characteristics
We retrieved 19 cases treated between July 2007 and May 2014.
Patient characteristics and tumor features are presented in Tables I
and II, respectively. Patients were 15 women (79%) and four men
(21%), with a median age of 69 years (range, 66–76). Thirteen (68%)
patients had locoregional disease, while 6 (32%) had synchronous
distant metastases. Tumor location was as follows: skin (n¼ 8
patients, five with scalp angiosarcoma), breast (n¼ 8 patients, two
with primary breast angiosarcoma), and soft tissue (n¼ 3 patients)
(Figs. 1–3). In 12 (63%) patients, angiosarcoma developed within the
field of previous radiotherapy (administered for a different
malignancy). The median interval between radiotherapy and the
diagnosis of angiosarcoma was 8 years (range, 7–18). Six patients
(32%) had a history of chronic lymphoedema. We registered a total of
54 target lesions at baseline (median 2/patient, range 2–4), with tumor
size ranging from 1.5 to 3.5 cm (median, 2 cm). In two patients with
angiosarcoma of the scalp, further superficial metastases were
present, but they were not included among target lesions due ill-
defined borders and lack of reliability in measurement. Fifty (92%)
tumors represented a local recurrence at the site of previous surgical
resection. In these patients, the median local relapse-free interval was
3.5 months (range, 2–10); relapse-free interval was longer in patients
with R0 than R1 resection, 5.5 months (range, 2–11) versus 2.8
months (range, 1–6), respectively. The median distant relapse-free
survival following surgical resection was 6 months (range, 2–17).
Treatment
Seven (37%) patients underwent ECT under general anaesthesia,
whereas 12 (63%) under mild general sedation. One patient was
receiving concomitant beyond progression paclitaxel chemotherapy
at the time of ECT with palliative intent, because of treatment option
exhaustion. The median hospital stay was 2 days (range, 1–3). After
an interval of at least 2 months after ECT, all patients received
additional treatments, according to disease extension, general
conditions and physician choice. In particular, 15 patients had no
further ECT, two patients received a second ECT cycle and two
patients received up to three ECT cycles; six patients (32%) received
systemic treatment, after a median interval of 8.1 months (range,
6.5–9.4), due to superficial disease progression not amenable with
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additional ECT or occurrence of distant metastases. Systemic
therapies included gemcitabine (n¼ 3 patients), docetaxel (n¼ 1
patient), and pazopanib (n¼ 2 patients). At the last follow-up, five of
these six patients showed disease progression.
Local Tumor Response
Two months after ECT, an objective response was observed in 47
(85.5%) of 54 target lesions, including 36 (66.7%) with CR and 10
(18.5%) with PR. Five tumors (9.3%) had SD and 3 (5.6%) showed
progressive disease (PD). As a result, 12 out of 19 patients (63%) were
responsive to treatment: 8 (42%) reported CR, 4 (21%) PR, 6 (32%) SD,
and 1 (5%) PD (Fig. 1–3).
In five of seven patients who initially achieved SD, we subsequently
observed a PR, after a median interval of 3 months (range, 3–7) (Fig. 4).
One of these five patients finally achieved local CR at 6 months
while receiving systemic treatment with docetaxel, which was started
3 months after ECT. The outcome of the remaining two patients who
initially had SD was as follows: one patient experienced disease
progression 2.2 months after treatment, the other one maintained SD
until his death, which occurred 7 months after ECT (Fig. 4).
Overall, in the 17 responsive patients, tumor regression was
observed after a median interval of 31 days (range, 28–210 days) from
the first ECT cycle.
In the five patients who were previously irradiated for angiosarcoma,
local tumor response to ECTwas as follows: CR in two cases, PR in two
cases, no response in the patient who was receiving concomitant
systemic treatment with paclitaxel.
The outcome of patients (n¼ 3) with soft tissue angiosarcomas was
as follows: one patient achieved CR, and two patients PR (Fig. 4). The
first patient, who was treated for a soft tissue angiosarcoma of the
shoulder, remained local disease-free for over 2 years, until his death.
The second patient achieved PR which was subsequently consolidated
by the administration of further systemic treatment, thus leading to CR;
the patient survived nearly 20 months after ECT. In the third patient, we
observed disease progression 6 months after ECT; a second cycle of
treatment was administered, with no response.
We did not observe any association between previous radiation and
response rate (P¼ 0.38) or complete response rate (P¼ 1.0) to ECT.
The response rate was 5/5 (100%) and 12/14 (86%) in patients with G2
and G3 angiosarcomas, respectively (P¼ 1.0); the CR rate was 4/4
(80%) versus 4/14 (29%), respectively (P¼ 0.11)
Tumor Control
Local failure (i.e., recurrence or progression within ECT field)
occurred in four and two patients, respectively, after a median interval
of 4.5 months (range, 2–9) (Fig. 4). Two of these six patients underwent
a second ECT cycle: the first patient achieved a CR with durable (>6
months) local control, while the other proved unresponsive and
developed further metastases shortly thereafter; salvage surgery was
attempted with palliative intent. Five out of 19 patients (26.3%)
developed out-of-field progression, after a median interval of 5.9
months (range, 4.7–12.8). For this reason, two of these five patients
received up to three ECT cycles with partial response and durable local
control. After a median follow-up of 12 months (range, 3–48), 1-year
TABLE I. Patient Characteristics (n¼ 19)
Characteristic Pts %
Sex
Female 15 79
Male 4 21
Age, years
Median 69
Range 66–76
Site of primary disease
Scalp 5 26
Breasta 8 42
Skin, other sites 3 16
Soft tissue 3 16
AJCC stage at diagnosis
IB 1 5
IIA 5 26
IIB 3 16
III 9 48
IV 1 5
FNCLCC Grade
1–2 5 26
3 14 74
Presentation
Primary 6 2
Secondaryb 13 68
Disease stage at enrollment
Locally advanced disease 13 68
Metastatic disease 6 32
Lung 3 16
Liver 1 5
Soft tissue 2 11
Focality
Solitary 7 37
Multifocal 12 63
Specific clinical presentations
Irradiated fieldc 12 63
Chronic lymphoedemad 6 32
Previous treatments
S 11 58
SþCT 3 16
SþRT 2 11
SþRTþCT 1 5
RT 2 10
Radicality of resection (n¼ 17)
R0 11 65
R1 6 35
S, surgery; CT, chemotherapy; RT, radiotherapy.
aTwo patients had primary angiosarcoma of the breast.
bPrimary tumors included: breast cancer (n¼ 9 patients), squamous cell
carcinoma (n¼ 2 patients), colorectal cancer (n¼ 1 patients), melanoma (n¼ 1
patient).
cThe median interval time from RT was 8.5 years (range, 7–10.8).
dLocation of lymphoedema was: trunk (n¼ 3 patients) and limbs (n¼ 3 patients).
TABLE II. Tumor Characteristics and Outcomes
Characteristic No. %
No. of treated tumors (target lesions) 54 100
No. per patient
Median 2
Range 1–4
Anatomical site
Scalp 5 9
Upper limb 7 13
Chest wall 38 70
Abdominal wall 4 8
Size, cm
Median 2
Range 1.5–3.5
Response to ECT
CR 43 80
PR 7 13
SD 4 7
Time to response, days
Median 31
Range 28–41
Response duration, months
Median 6.5
Range 4.3–15.3
ECT, electrochemotherapy; CR, complete response; PR, partial response; SD,
stable disease; LPFS, local progression-free survival.
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LPFS was 68% (95%CI 41–94%) (Supplemental Fig. S1). The local
failure rate in patients who received only ECT was higher compared to
patients who received further systemic treatment after ECT (5/12 (42%)
versus 1/7 (14%), respectively, P¼ 0.33). At the last follow-up, the
local response rate in patients (n¼ 13) who received ECT alone was
comparable to patients (n¼ 6) who received further oncological
treatments, 9/13 (69.2%) versus 4/6 (66.7%), respectively (P¼ 0.91).
One-year PFS in the whole cohort was 45% (95%CI 12–69%)
(Supplemental Fig. S1).
Toxicity
No serious adverse events were reported during the procedure and
hospital stay. Nine patients developed different grades of cutaneous
toxicity: G1 (n¼ 6 patients, 32%, with erythema, tissue oedema and
skin ulceration); G2 (n¼ 1 patient, 5%, with skin ulceration); and G3
(n¼ 2 patients, 11%, with skin ulceration requiring wound dressing for
4 and 6months, respectively). Both patients who reported G3 ulceration
had tumors located on the upper limb and a history of previous
Fig. 1. Locally recurrent, multifocal angiosarcoma of the scalp. Baseline presentation of two target lesions treated by electrochemotherapy
(A, D). Tumor shrinkage and residual skin ulcer at 1 month following treatment (B, E); wound healing and long lasting tumor response after
6 months (C, E).
Fig. 2. Cutaneous angiosarcoma in a patient with previous penile squamous cell carcinoma treated with radiotherapy. Local recurrence on the
abdominal wall after previous excision and radiation (A); necrotic tumor 15 days after ECT (B); complete regression after 2 months (C); the patient
was disease-free at 36 months (D).
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radiotherapy; they also received cytotoxic chemotherapy following
ECT. There was a trend for more frequent and more severe toxicity in
patients who were previously irradiated for angiosarcoma compared
with those who were not (4/4 vs. 5/10, respectively, P¼ 0.03). In
irradiated patient skin toxicity grade was G1, G2, G3, and G3; in non-
irradiated patients, skin toxicity was G1 in all cases. All the toxicities
resolved within 6 months.
In 10 patients (52.6%), treated tumors were reported to be
moderately to highly painful at the time of enrollment (Fig. 5). Two
months after ECT, pain level was significantly reduced and was
indicated as “moderate” by only four patients (P¼ 0.01). Out of 54
target lesions, 7 (13%) were bleeding at baseline; at the last follow-up,
in five of these seven tumors bleeding was controlled; intermittent
bleeding was still reported by a single patient with two lesions. Overall,
only one out of 6 patients with bleeding tumors at baseline did not have
hemostasis at last follow-up.
Patient Outcome
Visceral metastases developed in 4 out of 19 (21%) patients, after an
interval of 6, 6, 8, and 14 months, respectively. At the last follow-up,
patient status was as follows: disease-free, n¼ 4; alive with local
Fig. 3. Multifocal recurrence of radiation-induced mammary angiosarcoma. Skin metastases at the site of previous surgical excisions (A). Large
scabs 1 month after ECT (B); Partial response after 2 months (C); the patient was local disease-free 8 months after ECT (D).
Fig. 4. Patient reported pain levels before and after ECT. Post-ECT assessment was performed at the first follow-up visit, after a median time of
29 days (range, 23–46). Pain intensity was graded by means of a 10-point Verbal Numerical Rating Scale (VNRS) as follows: 0, no pain; 1–2, mild
pain; 3–6, moderate pain; 7–10, severe pain.
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disease, n¼ 5; dead of disease, n¼ 10. Median OS after ECT of the
entire cohort was 12 months (range, 4–44); OS was longer in patients
with locally advanced compared with metastatic disease, 17 (range,
8–44) versus 8.8 (range, 4–16) months, respectively (P¼ 0.10). The
median OS since the diagnosis of primary angiosarcoma was 29.9
months (range, 14.0–49.8).
DISCUSSION
This study examined, for the first time, outcomes associated with use
of ECT in angiosarcoma patients. According to our results, ECT seems
a promising treatment modality for providing effective local tumor
control and symptom palliation in angiosarcoma patients. In fact, it
ensured durable disease stabilization in 9 out 19 of our patients (Fig. 5),
while causing relevant, although transient, toxicity in only two cases.
Taking into account the number of local failures (n¼ 6 patients) and the
number of out-of-field relapses (n¼ 5 patients), we can roughly
estimate that a quarter of patients derived a clinical benefit from local
treatment with ECT. In particular, these patients achieved durable (6
months) and effective tumor control, without experiencing relevant skin
toxicity. These results may have implications for the management of
angiosarcoma patients. In fact, since locally advanced/metastatic
angiosarcoma has poor prognosis and treatment is considered
palliative in most cases, tolerability of applied intervention is crucial.
Radical resection represents the mainstay of treatment, possibly in
the frame of a multimodal approach [25,26]. Unfortunately, in
everyday practice most patients are elderly and often inoperable or
unfit for conventional oncological treatments. ECT is an emerging
skin-directed therapy with proven efficacy across malignancies—
mainly in melanoma [27],—and a favorable toxicity profile [28].
Before our analysis, it was unclear whether ECT with bleomycin had
activity in angiosarcomas. Due to some intrinsic constraints (i.e., the
length of the electrodes for electric pulse delivery), our series mainly
accounts for patients with superficial tumors, such as cutaneous and
breast angiosarcomas. Before ECT, most patients received surgery as
the exclusive treatment for recurrence. It is conceivable that previous
radiotherapy (12/19 patients) as well as patient age and associated
morbidities could have prevented physicians from more aggressive
treatment. Woefully, the median interval between surgical resection
and subsequent local failure was 3.5 months, which is consistent with
the time to local recurrence reported by Jallali et al. [11] in patients
with radiation-induced angiosarcoma after a microscopically
incomplete excision. It is conceivable that precocity of relapse in
our patients could have been related to the high rate (35%) of R1
resections and to the avoidance or impossibility to administer
adjuvant therapies. A radical treatment is an established prognostic
factor in angiosarcoma [15,25,26], therefore the introduction of an
effective therapy could be beneficial in patients who cannot receive
radical resection. Despite the inherent limitations of a retrospective
analysis based on small numbers, our data suggest that ECT with
bleomycin has sustained activity in this tumor. In fact, more than 80%
of electroporated tumors were responsive to the first cycle of
treatment and up to 67% of them showed complete regression. As a
result, a high percentage of patients were responsive to ECT. This
favorable early outcome was achieved without concomitant systemic
therapies and irrespective of previous radiotherapy. Notably, tumor
shrinkage was precocious, after a median interval of 30 days
following treatment. Noteworthy, tumor control was durable (>6
months) in about half of patients (Fig. 4). Our 68% 1-year LPFS
compares favorably with PFS indicated for currently available
systemic agents, such as doxorubicin, paclitaxel and
bevacizumab [29,30]. Notwithstanding, our data on local tumor
control may have been influenced by the small sample and patient
heterogeneity and should therefore be considered with caution.
Fig. 5. Swimmer plot graph of time to and durability of local tumor response of baseline tumors. Each bar represents one patient. A durable
responder (indicated by & symbol on the left of the “y” axis) is a subject who had confirmed response for at least 6 months. A patient who
experienced disease recurrence outside the ECT field is indicated by  symbol (additional ECT cycles applied on out-of-field recurrences are not
shown). A patient who experienced local failure (disease progression or relapse) within ECT field is indicated by* symbol on the bar. The bars n°
2, 6, 11, 14, 17 (starting from the top) correspond to the patients whowere previously irradiated for angiosarcoma. The bars n° 2, 5, 11 (starting from
the top) correspond to the patients with angiosarcomas of the soft tissue. The bar n° 14 (starting from the top) indicate the single patient who was
receiving concomitant treatment with paclitaxel at the time of ECT.
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Interestingly, we observed a symptomatic benefit in five out six
patients with bleeding tumors, an effect which was likely due to the
strong ECT anti-vascular effect. Moreover, we also observed an
improvement of tumor-associated pain figures (Fig. 5), which is a
relatively common complaint of patients with superficial
angiosarcoma [16]. Generally, treatment-induced pain is one of the
most relevant concerns with ECT, although it is well tolerated in most
patients [28]. Overall, we observed a tendency for more frequent and
more severe dermatologic side effects in previously irradiated patients.
G3 skin ulceration was reported in two patients, who were both
previously irradiated; in these patients, wound healing may have also
been hampered by subsequent chemotherapy. The possibility to
efficiently control superficial metastases, coupled with the favorable
toxicity profile and ease of administration, make thus ECT a reasonable
option also in patients with visceral metastases.
Standard chemotherapeutic agents for metastatic angiosarcoma
include doxorubicin, ifosfamide, and taxanes [29]. In recent years, the
inhibition of the vascular endothelial growth factor pathway has
emerged as a rational strategy [30]. However, response rates remain
invariably low (doxorubicin, 30%; paclitaxel, 18–62%; bevacizumab,
17%). On the other hand, angiosarcoma rich vasculature and superficial
localization allow for optimal exploitation of ECT anti-vascular
effects [19,20]. In radiation-associated sarcomas, the association of
re-irradiation and hyperthermia produced a response rate of 75%, but
with relevant toxicities [26]. In patients with scalp angiosarcoma,
different strategies based on radiotherapy (total scalp irradiation with
X-rays and electrons, radiotherapy combined with interleukin-2
immunotherapy, and definitive radiotherapy combined with
docetaxel) have been explored, unfortunately without definitive
results [31–33]. Compared with these options, ECT has a number of
advantages. It does not require dedicated facilities or specific expertise;
it’s a 1-day treatment that can be delivered in a day-hospital or
outpatient setting; it can be repeated several times, the main limiting
factor being the cumulative dose of bleomycin (400,000 IU/m2).
Nevertheless, clinicians should be aware that bleomycin limiting
toxicity is exerted on the lung. In fact, this drug may induce severe
toxicity that should not be underestimated, particularly in elderly
patients or in those who were previously irradiated. For these reason,
patient age, renal function and previous bleomycin exposure are crucial
information in patient selection for ECT.
In our study, 6 out of 19 patients developed in-field recurrence
(n¼ 4) or progression (n¼ 2). Two of them received a second ECT
cycle, which ensured durable local remission in one patient (Fig. 5,
patient #1). Thanks to its antivascular effect, ECT also represents a
valuable palliative tool for patients with bleeding tumors as well as a
highly active treatment in patients with Kaposi sarcoma [21,22]. In
order for ECT to be effective, two conditions must be met: (i) an
adequate drug concentration at tumor site and (ii) an adequate
coverage of the target area with electric voltage. For these reasons,
most angiosarcomas represent an ideal target for percutaneous
treatment with ECT.
In future, an intriguing aspect will be the investigation of ECT
outcome in relation with the local immune infiltrate. According to a
recent study, tumor-infiltrating lymphocytes (TILs), in particular
CD8þ, seem to be the most relevant immune cell population
affecting the prognosis of cutaneous angiosarcoma patients [33].
Interestingly, ECT has been shown to elicit a local immune response in
melanoma patients and TILs distribution (a brisk pattern) and their
phenotype (CD8 expression) were associated with a higher probability
of response to treatment [34]. Interestingly, according to Maddox
et al. [8] although most angiosarcomas had a no-brisk lymphocytic
infiltrate, those with a marked infiltrate showed a significantly longer
interval to recurrence. There is no question that the present report has
unavoidable weaknesses, due to small numbers, the retrospective
fashion, as well as patient heterogeneity. Despite these limitations,
however, our study indicates sustained response rate with ECT in a
difficult-to-treat malignancy with limited therapeutic options.
Moreover, our study involved centers that have long used ECT
according to a shared protocol and that conduct studies with ECT also in
other tumors [35,36].
In conclusion, our results indicate that ECT exerts sustained
antitumor activity in angiosarcomas. It ensured durable local control in
about a half of patients in our study. In fact, 9/19 patients experienced
durable local tumor control and five of them remained also free from
out-of-field progression. Symptom benefits included bleeding control
and local pain relief. Based on these favorable results, we envision that
ECT could be further tested in appropriately designed trials. Further
collaborative efforts will help to clarify the role of this treatment
modality for improving local control and patient outcome in this
challenging disease.
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